PTIX — Protagenic Therapeutics, Inc.

Summary of PTIX Q4 2023 Earnings Call

1. Key Financial Results and Metrics

• Q4 2023 R&D Spending: $1.0 million, a 301% increase from $258,000 in Q4 2022, driven by the initiation of clinical trials for PT00114.
• G&A Spending: $201,000, down 50% from the previous year, attributed to minimal stock-based compensation.
• Net Loss: $1.2 million for Q4 2023, compared to a net loss of $656,000 in Q4 2022.
• Full Year R&D Spending: $3.3 million, up 109% from $1.6 million in 2022.
• Full Year Net Loss: $4.5 million, a 27% increase from the previous year, primarily due to higher R&D expenses.
• Cash Position: Ended 2023 with $4.1 million in cash, down from $8.0 million at the end of 2022, sufficient to fund the ongoing Phase 1 clinical trial.

2. Strategic Updates and Business Highlights

• Clinical Trial Initiation: PT00114, a novel drug candidate targeting neuropsychiatric disorders, entered its first clinical trial in 2023.
• Mechanism of Action: PT00114 is an analog of Teneurin C-terminal associated peptide (TCAP) and is designed to address anxiety, depression, PTSD, and addiction with potentially fewer side effects than existing treatments.
• Preclinical Success: Strong preclinical data supports PT00114's efficacy in modulating stress responses and improving mental health outcomes.
• Collaboration: Engaging with experts, including Dr. Maurizio Fava from Harvard, to enhance clinical trial design and execution.

3. Forward Guidance and Outlook

• 2024 Focus: Execution of Phase 1 clinical trials and preparation for proof-of-concept efficacy studies in various neuropsychiatric conditions.
• Clinical Trial Timeline:
  • Completion of enrollment for the Single Ascending Dose (SAD) study by the end of April 2024, with data readout expected by mid-May.
  • Multiple Ascending Dose (MAD) study to begin enrollment immediately after SAD completion, with results anticipated in early Q3 2024.
• Regulatory Steps: Finalizing Phase 2 protocol for submission to regulatory agencies, with confidence in safety and efficacy based on preclinical data.

4. Bad News, Challenges, or Points of Concern

• Increased Losses: The company reported a higher net loss year-over-year, reflecting increased investment in R&D without immediate revenue generation.
• Cash Burn Rate: The significant decrease in cash reserves raises concerns about funding future operations beyond the current clinical trial, necessitating potential fundraising efforts.
• Regulatory Risks: While confident in the safety profile, any delays or issues in regulatory approvals for Phase 2 could impact timelines and funding needs.

5. Notable Q&A Insights

• Clinical Trial Readouts: The SAD and MAD studies are expected to provide data on safety and efficacy, with cortisol levels being a key biomarker to be reported alongside results.
• Regulatory Strategy: The Phase 2 studies will likely adopt a "basket trial" approach to evaluate efficacy across multiple neuropsychiatric disorders, which is generally well-received by regulatory bodies.
• Biomarker Data Collection: While primarily focused on safety in healthy volunteers, the company is collecting biomarker data to assess neuroprotective effects, with plans to disclose cortisol levels in future updates.

Overall, PTIX is positioned for a pivotal year ahead as it advances its clinical trials for PT00114, although it faces challenges related to financial sustainability and regulatory navigation.